Trial Profile
Low dose metronomic cyclophosphamide and capecitabine in pretreated metastatic breast cancer patients.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Cyclophosphamide (Primary)
- Indications Breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms metroCX
- 09 Feb 2012 New trial record